Phio Pharmaceuticals Corp. (PHIO) |
|
3.51 -0.52 (-12.9%)
|
05-31 11:52 |
|
Open: |
3.59 |
Pre. Close: |
4.03 |
|
High:
|
3.59 |
Low:
|
3.38 |
|
Volume:
|
129,571 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 11:18:53 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.33 One year: 8 |
| Support: |
Support1: 3.1 Support2: 2.58 |
| Resistance: |
Resistance1: 5.42 Resistance2: 6.84 |
| Pivot: |
3.99  |
| Moving Average: |
MA(5): 3.9 MA(20): 3.99
MA(100): 5.27 MA(250): 6.45 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2  |
| Stochastic oscillator: |
%K(14,3): 14.3 %D(3): 16.9 |
| RSI: |
RSI(14): 41.9 |
| 52-week: |
High: 12.27 Low: 3.1 |
| Average Vol(K): |
3-Month: 600 (K) 10-Days: 2,877 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PHIO ] has closed above bottom band by 16.6%. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.11 - 4.13 |
4.13 - 4.15 |
|
Low:
|
3.76 - 3.79 |
3.79 - 3.82 |
|
Close:
|
3.98 - 4.03 |
4.03 - 4.07 |
|
Company Description |
|
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. |
Headline News |
Wed, 31 May 2023
CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights ... - PR Newswire
Wed, 31 May 2023
Phio Pharmaceuticals slides on equity offering (NASDAQ:PHIO) - Seeking Alpha
Wed, 31 May 2023
Phio Pharmaceuticals Shares Drop 16% After Stock Offerings Price - MarketWatch
Wed, 31 May 2023
Phio Pharmaceuticals Announces $4 Million Concurrent Registered ... - PR Newswire
Fri, 26 May 2023
Soligenix Receives Compliance Confirmation from Nasdaq - Best Stocks
Thu, 25 May 2023
Should You Sell Phio Pharmaceuticals Corp (PHIO) Stock Thursday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.1 (%) |
|
% Held by Institutions
|
3.1 (%) |
|
Shares Short
|
30 (K) |
|
Shares Short P.Month
|
19 (K) |
Stock Financials |
|
EPS
|
-10.86 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.52 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.11 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.32 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.36 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
